Simplify Asset Management Inc. Buys 23,866 Shares of Gilead Sciences, Inc. $GILD

Simplify Asset Management Inc. lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 63.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 61,345 shares of the biopharmaceutical company’s stock after purchasing an additional 23,866 shares during the quarter. Gilead Sciences accounts for approximately 0.1% of Simplify Asset Management Inc.’s investment portfolio, making the stock its 22nd largest position. Simplify Asset Management Inc.’s holdings in Gilead Sciences were worth $8,550,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of GILD. Norges Bank bought a new stake in shares of Gilead Sciences in the 4th quarter worth about $2,617,152,000. Boston Partners bought a new stake in Gilead Sciences during the fourth quarter worth approximately $517,808,000. Massachusetts Financial Services Co. MA increased its stake in Gilead Sciences by 3,763.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after acquiring an additional 4,113,999 shares during the last quarter. Bank of America Corp DE raised its position in Gilead Sciences by 15.2% during the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock valued at $2,837,948,000 after purchasing an additional 3,046,688 shares during the period. Finally, Vanguard Group Inc. raised its position in Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after purchasing an additional 2,113,692 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the sale, the chief executive officer owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. This trade represents a 2.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 83,000 shares of company stock valued at $10,824,500 in the last three months. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $131.27 on Friday. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The company has a market cap of $162.98 billion, a P/E ratio of 17.88 and a beta of 0.32. The firm’s 50 day moving average price is $129.44 and its 200-day moving average price is $134.53. Gilead Sciences, Inc. has a 52-week low of $107.75 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same period last year, the business earned $1.81 EPS. Gilead Sciences’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, sell-side analysts predict that Gilead Sciences, Inc. will post -0.8 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were paid a dividend of $0.82 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on GILD shares. Rothschild & Co Redburn decreased their price target on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a research note on Wednesday, May 20th. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Gilead Sciences in a research report on Monday, June 8th. Daiwa Securities Group lowered their target price on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, May 19th. Finally, The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research note on Friday, April 17th. Twenty-five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $158.41.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.